1. Home
  2. GWRE vs GMAB Comparison

GWRE vs GMAB Comparison

Compare GWRE & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guidewire Software Inc.

GWRE

Guidewire Software Inc.

HOLD

Current Price

$210.75

Market Cap

18.1B

Sector

Technology

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$31.74

Market Cap

17.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GWRE
GMAB
Founded
2001
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1B
17.4B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
GWRE
GMAB
Price
$210.75
$31.74
Analyst Decision
Buy
Strong Buy
Analyst Count
13
6
Target Price
$272.25
$40.40
AVG Volume (30 Days)
705.3K
1.4M
Earning Date
12-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
191.31
132.41
EPS
1.06
25.10
Revenue
$1,272,197,000.00
$3,845,670,022.00
Revenue This Year
$18.42
$24.85
Revenue Next Year
$15.17
$16.67
P/E Ratio
$198.50
$12.31
Revenue Growth
22.80
29.57
52 Week Low
$165.09
$17.24
52 Week High
$272.60
$33.65

Technical Indicators

Market Signals
Indicator
GWRE
GMAB
Relative Strength Index (RSI) 37.89 59.84
Support Level $204.08 $31.32
Resistance Level $229.85 $32.41
Average True Range (ATR) 7.42 0.64
MACD 0.52 0.11
Stochastic Oscillator 25.88 73.67

Price Performance

Historical Comparison
GWRE
GMAB

About GWRE Guidewire Software Inc.

Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: